|
1
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baybutt TR, Aka AA and Snook AE:
Immunotherapy in colorectal cancer: Where are we now? Curr
Colorectal Cancer Rep. 13:353–361. 2017. View Article : Google Scholar
|
|
3
|
Overman MJ, Ernstoff MS and Morse MA:
Where we stand with immunotherapy in colorectal cancer: Deficient
mismatch repair, proficient mismatch repair, and toxicity
management. Am Soc Clin Oncol Educ Book. 38:239–247. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zumwalt TJ and Goel A: Immunotherapy of
metastatic colorectal cancer: Prevailing challenges and new
perspectives. Curr Colorectal Cancer Rep. 11:125–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le DT, Hubbard-Lucey VM, Morse MA, Heery
CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA
Jr, et al: A blueprint to advance colorectal cancer
immunotherapies. Cancer Immunol Res. 5:942–949. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Becht E, de Reyniès A, Giraldo NA, Pilati
C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P
and Fridman WH: Immune and stromal classification of colorectal
cancer is associated with molecular subtypes and relevant for
precision immunotherapy. Clin Cancer Res. 22:4057–4066. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frey DM, Droeser RA, Viehl CT, Zlobec I,
Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L and
Tornillo L: High frequency of tumor-infiltrating FOXP3(+)
regulatory T cells predicts improved survival in mismatch
repair-proficient colorectal cancer patients. Int J Cancer.
126:2635–2643. 2010.PubMed/NCBI
|
|
9
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic significance in
colorectal cancer. J Clin Oncol. 27:186–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
deLeeuw RJ, Kost SE, Kakal JA and Nelson
BH: The prognostic value of FoxP3+ tumor-infiltrating lymphocytes
in cancer: A critical review of the literature. Clin Cancer Res.
18:3022–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang X, Liu M, Luo X, Zhu M, Huang S and
Pan X: The prognostic value of a tumor microenvironment-based
immune cell infiltration score model in colon cancer. Front Oncol.
11:7288422021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ghiringhelli F and Fumet JD: Is there a
place for immunotherapy for metastatic microsatellite stable
colorectal cancer? Front Immunol. 10:18162019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu Y, Zuo W, Shen X, Liu Y, Zhao Y, Xiong
Y, Cao H, Wang Y and Liang Z: NF-κB is involved in the regulation
of autophagy in mutant p53 cells in response to ionizing radiation.
Cell Death Discov. 7:1592021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu H, Mohan S and Natarajan M:
Radiation-triggered NF-κB activation is responsible for the
angiogenic signaling pathway and neovascularization for breast
cancer cell proliferation and growth. Breast Cancer (Auckl).
6:125–135. 2012.PubMed/NCBI
|
|
15
|
Huang TT, Wuerzberger-Davis SM, Seufzer
BJ, Shumway SD, Kurama T, Boothman DA and Miyamoto S: NF-kappaB
activation by camptothecin. A linkage between nuclear DNA damage
and cytoplasmic signaling events. J Biol Chem. 275:9501–9509. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brea-Calvo G, Siendones E, Sanchez-Alcázar
JA, de Cabo R and Navas P: Cell survival from chemotherapy depends
on NF-kappaB transcriptional up-regulation of coenzyme Q
biosynthesis. PLoS One. 4:e53012009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsuoka S, Ballif BA, Smogorzewska A,
McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini
N, Lerenthal Y, et al: ATM and ATR substrate analysis reveals
extensive protein networks responsive to DNA damage. Science.
316:1160–1166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Flynn RL and Zou L: ATR: A master
conductor of cellular responses to DNA replication stress. Trends
Biochem Sci. 36:133–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel SA and Minn AJ: Combination cancer
therapy with immune checkpoint blockade: Mechanisms and strategies.
Immunity. 48:417–433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorzo A, Galos D, Volovat SR, Lungulescu
CV, Burz C and Sur D: Landscape of immunotherapy options for
colorectal cancer: Current knowledge and future perspectives beyond
immune checkpoint blockade. Life (Basel). 12:2292022.PubMed/NCBI
|
|
22
|
Zhou C, Jiang T, Xiao Y, Wang Q, Zeng Z,
Cai P, Zhao Y, Zhao Z, Wu D, Lin H, et al: Good tumor response to
chemoradioimmunotherapy in dMMR/MSI-H advanced colorectal cancer: A
case series. Front Immunol. 12:7843362021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Young KH, Baird JR, Savage T, Cottam B,
Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS,
et al: Optimizing timing of immunotherapy improves control of
tumors by hypofractionated radiation therapy. PLoS One.
11:e01571642016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang W, Wu L, Zhang J, Wu H, Han E and Guo
Q: Chemoimmunotherapy by combining oxaliplatin with immune
checkpoint blockades reduced tumor burden in colorectal cancer
animal model. Biochem Biophys Res Commun. 487:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas J, Leal A and Overman MJ: Clinical
development of immunotherapy for deficient mismatch repair
colorectal cancer. Clin Colorectal Cancer. 19:73–81. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shahda S, Noonan AM, Bekaii-Saab TS,
O'Neil BH, Sehdev A, Shaib WL, Helft PR, Loehrer PJ, Tong Y, Liu Z,
et al: A phase II study of pembrolizumab in combination with
mFOLFOX6 for patients with advanced colorectal cancer. J Clin
Oncol. 35 (15 Suppl):S35412017. View Article : Google Scholar
|
|
27
|
Sahin IH, Akce M, Alese O, Shaib W,
Lesinski GB, El-Rayes B and Wu C: Immune checkpoint inhibitors for
the treatment of MSI-H/MMR-D colorectal cancer and a perspective on
resistance mechanisms. Br J Cancer. 121:809–818. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Samuel T, Fadlalla K, Gales DN, Putcha BD
and Manne U: Variable NF-κB pathway responses in colon cancer cells
treated with chemotherapeutic drugs. BMC Cancer. 14:5992014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bedi D, Henderson HJ, Manne U and Samuel
T: Camptothecin induces PD-L1 and immunomodulatory cytokines in
colon cancer cells. Medicines (Basel). 6:512019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang P, Su DM, Liang M and Fu J:
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1)
surface expression in breast cancer cells and promote
PD-L1-mediated T cell apoptosi. Mol Immunol. 45:1470–1476. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Der Kraak L, Goel G, Ramanan K,
Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS,
Davison JM, et al: 5-Fluorouracil upregulates cell surface B7-H1
(PD-L1) expression in gastrointestinal cancers. J Immunother
Cancer. 4:652016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwai T, Sugimoto M, Wakita D, Yorozu K,
Kurasawa M and Yamamoto K: Topoisomerase I inhibitor, irinotecan,
depletes regulatory T cells and up-regulates MHC class I and PD-L1
expression, resulting in a supra-additive antitumor effect when
combined with anti-PD-L1 antibodies. Oncotarget. 9:31411–31421.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato H, Niimi A, Yasuhara T, Permata TBM,
Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, et al:
DNA double-strand break repair pathway regulates PD-L1 expression
in cancer cells. Nat Commun. 8:17512017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC
and Liu LF: Chemotherapeutics and radiation stimulate MHC class I
expression through elevated interferon-beta signaling in breast
cancer cells. PLoS One. 7:e325422012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou Y, Bastian IN, Long MD, Dow M, Li W,
Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, et al: Activation
of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through
induction of MHC-I antigen presentation. Proc Natl Acad Sci USA.
118:e20258401182021. View Article : Google Scholar : PubMed/NCBI
|
